Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

Francisco Javier González-Barcalaa Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain;b Respiratory Medicine, Universidad de Santiago de Compostela, Santiago de Compostela, Spain

Xavier Muñoz-Gallc Department of Pulmonology, Hospital Universitari Vall d’Hebron, Barcelona, Spain;d CIBER of Respiratory Diseases (CIBERes), Madrid, Spain;e Cell Biology, Physiology, and Immunology, Universidad Autónoma de Barcelona, Barcelona, SpainCorrespondence[email protected]

Esther Mariscalf GlaxoSmithKline, Madrid, Spain

Andrea Garcíaf GlaxoSmithKline, Madrid, Spain

Shibing Yangg GlaxoSmithKline, Collegeville, PA, USA

Gijs van de Weteringh Pharmerit International, Rotterdam, the Netherlands

José Luis Izquierdo-Alonsoi Medicine and Specialities Department, Universidad de Alcalá (Alcalá de Henares, Madrid), Hospital Universitario Guadalajara, Guadalajara, Spain

show all

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date